Tracy Cunningham
Chief Tech/Sci/R&D Officer chez AMRYT PHARMA PLC
Profil
Tracy Cunningham is currently the Director at Health Research Board and the Chief Medical Officer at Amryt Pharma Plc.
Previously, she worked as the Clinical Head-Oncology Research & Development at AstraZeneca PLC and as the Vice President & Head-Development at Amryt Pharma Holdings Ltd.
Dr. Cunningham completed her undergraduate degree at the Royal College of Surgeons.
Postes actifs de Tracy Cunningham
| Sociétés | Poste | Début |
|---|---|---|
| AMRYT PHARMA PLC | Chief Tech/Sci/R&D Officer | 01/04/2020 |
| Health Research Board | Director/Board Member | - |
Anciens postes connus de Tracy Cunningham
| Sociétés | Poste | Fin |
|---|---|---|
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Chief Tech/Sci/R&D Officer | - |
Formation de Tracy Cunningham
| Royal College of Surgeons | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
| Health Research Board | Government |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
Amryt Pharma Plc
 Amryt Pharma Plc Pharmaceuticals: MajorHealth Technology Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded on July 17, 2019 and is headquartered in Dublin, Ireland. | Health Technology |
